FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3141197331> ?p ?o ?g. }

• W3141197331 endingPage "S90" @default.
• W3141197331 startingPage "S80" @default.
• W3141197331 abstract "Hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine, after cytoreductive surgery, may reduce the tumor progression of pancreatic cancer through the reduction of the neoplastic volume and the subpopulation of residual pancreatic cancer stem cells, improving the survival of patients with pancreatic cancer and decreasing the recurrence of the disease.A pilot study is performed with the first ten patients in the experimental group. A randomized study (phase II-III clinical trial) that requires a population of 42 patients, with 21 patients in each group. All patients have a diagnosis of ductal adenocarcinoma of the pancreas, which will be surgically resected with curative intention. (I) Group I: after an R0 resection, patients receive individualized adjuvant treatments. (II) Group II: after an R0 resection, HIPEC is performed with gemcitabine (120 mg/m2 for 30 min), and they also receive individualized adjuvant treatments. To analyze the safety of the procedure, the main variables measured were as follows: grades of complications by means of the Clavien-Dindo system: pancreas surgery complications (e.g., pancreatic fistula, perioperative hemorrhage, delayed gastric emptying, biliary fistula), operative mortality, and laboratory parameters to control system functions. Values were measured three times: preoperatively, twenty-four hours after surgery, and on the 7th postoperative day.From 2018 to 2019, 31 patients were recruited for our clinical trial. Fifteen patients were excluded because of intraoperative unresectability or a different intraoperative histologic diagnosis. Ten patients were included in the experimental group (resection plus HIPEC gemcitabine). The mean age was 65±7 years, and six patients were female (60%). We confirmed the histologic diagnosis of ductal pancreatic adenocarcinoma in all patients prior to HIPEC. Total pancreatectomy was performed in five patients. The surgical median time was 360 min, and the hospital stay was 11 days. Four patients showed complications classified as Clavien-Dindo type II and one showing type I. Six patients were classified as having stage III tumors. To date, no hospital mortality, locoregional recurrence, or differences between the two groups in terms of perioperative complications, biochemical and gasometric values, or Clavien-Dindo complication grades were observed.Our clinical pilot study demonstrated a similar perioperative outcome that allows the trial until main objectives are achieved." @default.
• W3141197331 created "2021-04-13" @default.
• W3141197331 creator A5004898737 @default.
• W3141197331 creator A5013568680 @default.
• W3141197331 creator A5030085018 @default.
• W3141197331 creator A5040105917 @default.
• W3141197331 creator A5040467254 @default.
• W3141197331 creator A5042386828 @default.
• W3141197331 creator A5053675686 @default.
• W3141197331 creator A5063075531 @default.
• W3141197331 creator A5072220040 @default.
• W3141197331 creator A5078579053 @default.
• W3141197331 creator A5087572553 @default.
• W3141197331 creator A5089223589 @default.
• W3141197331 date "2021-04-01" @default.
• W3141197331 modified "2023-10-17" @default.
• W3141197331 title "Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41" @default.
• W3141197331 cites W1500827124 @default.
• W3141197331 cites W156132757 @default.
• W3141197331 cites W1912077767 @default.
• W3141197331 cites W1931508686 @default.
• W3141197331 cites W1965289838 @default.
• W3141197331 cites W1968710367 @default.
• W3141197331 cites W1986249544 @default.
• W3141197331 cites W1992514491 @default.
• W3141197331 cites W2005831812 @default.
• W3141197331 cites W2019264784 @default.
• W3141197331 cites W2025970479 @default.
• W3141197331 cites W2041629401 @default.
• W3141197331 cites W2041922465 @default.
• W3141197331 cites W2043103956 @default.
• W3141197331 cites W2052694101 @default.
• W3141197331 cites W2056953440 @default.
• W3141197331 cites W2060738125 @default.
• W3141197331 cites W2062069198 @default.
• W3141197331 cites W2066810823 @default.
• W3141197331 cites W2067243578 @default.
• W3141197331 cites W2077975597 @default.
• W3141197331 cites W2092388421 @default.
• W3141197331 cites W2092842111 @default.
• W3141197331 cites W2093268532 @default.
• W3141197331 cites W2094561096 @default.
• W3141197331 cites W2099023480 @default.
• W3141197331 cites W2102085111 @default.
• W3141197331 cites W2117288541 @default.
• W3141197331 cites W2131170195 @default.
• W3141197331 cites W2137449662 @default.
• W3141197331 cites W2147993276 @default.
• W3141197331 cites W2149861058 @default.
• W3141197331 cites W2165585598 @default.
• W3141197331 cites W2316886542 @default.
• W3141197331 cites W2361768834 @default.
• W3141197331 cites W2516970542 @default.
• W3141197331 cites W2519236617 @default.
• W3141197331 cites W2604320614 @default.
• W3141197331 cites W2620628410 @default.
• W3141197331 cites W2985784682 @default.
• W3141197331 doi "https://doi.org/10.21037/jgo-20-238" @default.
• W3141197331 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8100727" @default.
• W3141197331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33968428" @default.
• W3141197331 hasPublicationYear "2021" @default.
• W3141197331 type Work @default.
• W3141197331 sameAs 3141197331 @default.
• W3141197331 citedByCount "4" @default.
• W3141197331 countsByYear W31411973312021 @default.
• W3141197331 countsByYear W31411973312022 @default.
• W3141197331 countsByYear W31411973312023 @default.
• W3141197331 crossrefType "journal-article" @default.
• W3141197331 hasAuthorship W3141197331A5004898737 @default.
• W3141197331 hasAuthorship W3141197331A5013568680 @default.
• W3141197331 hasAuthorship W3141197331A5030085018 @default.
• W3141197331 hasAuthorship W3141197331A5040105917 @default.
• W3141197331 hasAuthorship W3141197331A5040467254 @default.
• W3141197331 hasAuthorship W3141197331A5042386828 @default.
• W3141197331 hasAuthorship W3141197331A5053675686 @default.
• W3141197331 hasAuthorship W3141197331A5063075531 @default.
• W3141197331 hasAuthorship W3141197331A5072220040 @default.
• W3141197331 hasAuthorship W3141197331A5078579053 @default.
• W3141197331 hasAuthorship W3141197331A5087572553 @default.
• W3141197331 hasAuthorship W3141197331A5089223589 @default.
• W3141197331 hasBestOaLocation W31411973311 @default.
• W3141197331 hasConcept C121608353 @default.
• W3141197331 hasConcept C126322002 @default.
• W3141197331 hasConcept C141071460 @default.
• W3141197331 hasConcept C2776694085 @default.
• W3141197331 hasConcept C2778764654 @default.
• W3141197331 hasConcept C2779458272 @default.
• W3141197331 hasConcept C2780210213 @default.
• W3141197331 hasConcept C2780258809 @default.
• W3141197331 hasConcept C2780427987 @default.
• W3141197331 hasConcept C2780911694 @default.
• W3141197331 hasConcept C2781182431 @default.
• W3141197331 hasConcept C2908647359 @default.
• W3141197331 hasConcept C2994223192 @default.
• W3141197331 hasConcept C31174226 @default.
• W3141197331 hasConcept C535046627 @default.
• W3141197331 hasConcept C71924100 @default.
• W3141197331 hasConcept C99454951 @default.

• next